Double trouble: how c-MET and HER2 fuel bladder cancer progression
Abstract Background Bladder cancer is still a prevalent, heterogeneous, and challenging disease. Most cases are non-muscle invasive and carry a significant risk of recurrence and progression despite current advances in therapeutic options. Main c-MET and HER2 belong to the receptor tyrosine kinase f...
Saved in:
| Main Authors: | E. M. Naguib, E. F. Ismail, D. I. Badran, M. H. Sherief, T. B. El-Abaseri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2024-12-01
|
| Series: | Egyptian Journal of Medical Human Genetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43042-024-00618-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NGS coverage accurately predicts MET and HER2 (ERBB2) gene amplifications in a real-world non-small cell lung cancer cohort
by: Adam Kowalewski, et al.
Published: (2025-07-01) -
Performance of a HER2 testing algorithm tailored for urothelial bladder cancer: A Bi-centre study
by: Aoling Huang, et al.
Published: (2024-12-01) -
CD44v, S1PR1, HER3, MET and cancer‐associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb
by: Takashi Nakano, et al.
Published: (2025-05-01) -
A radiomics-based interpretable machine learning model to predict the HER2 status in bladder cancer: a multicenter study
by: Zongjie Wei, et al.
Published: (2024-10-01) -
Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review
by: Jian-Hui Wu, et al.
Published: (2025-06-01)